Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Pathway Signaling

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Pathway Signaling PATHWAY OF THE MONTH Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Pathway Signaling Andrew Thorburn, DPhil also function as a decoy/inhibitor by sequestering TRAIL Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/ extracellularly. Much current interest in TRAIL derives from Apo1L is a death ligand, a cytokine that activates apoptosis through its roles in cancer development and treatment. In particular, cell surface death receptors. TRAIL is thought to be important in 1,2 recombinant TRAIL and agonistic antibodies that recog- host tumor surveillance and metastasis suppression, and various 3,4 nize TRAIL receptors have been shown to kill many tumor therapeutic agonists that activate TRAIL receptors to induce tumor cells while leaving most normal cells unscathed and display- cell apoptosis are in clinical development. This review discusses ing little toxicity when delivered systemically to animals and recent findings about TRAIL pathway signaling and relates the people. It is therefore hoped that these agents may be useful signaling mechanisms to issues that need to be considered as we try 5–7 to treat cancer. This contrasts with other death ligands, to manipulate TRAIL signaling to treat cancer. such as TNF or Fas ligand, which activate similar pathways using the same signaling proteins but display unacceptable (J http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Pathway Signaling

Thorburn, Andrew
Journal of Thoracic Oncology , Volume 2 (6) – Jun 1, 2007
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/tumor-necrosis-factor-related-apoptosis-inducing-ligand-trail-pathway-OrQtoCVUZT

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31805fea64
pmid
17545839
Publisher site
See Article on Publisher Site

Abstract

PATHWAY OF THE MONTH Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Pathway Signaling Andrew Thorburn, DPhil also function as a decoy/inhibitor by sequestering TRAIL Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/ extracellularly. Much current interest in TRAIL derives from Apo1L is a death ligand, a cytokine that activates apoptosis through its roles in cancer development and treatment. In particular, cell surface death receptors. TRAIL is thought to be important in 1,2 recombinant TRAIL and agonistic antibodies that recog- host tumor surveillance and metastasis suppression, and various 3,4 nize TRAIL receptors have been shown to kill many tumor therapeutic agonists that activate TRAIL receptors to induce tumor cells while leaving most normal cells unscathed and display- cell apoptosis are in clinical development. This review discusses ing little toxicity when delivered systemically to animals and recent findings about TRAIL pathway signaling and relates the people. It is therefore hoped that these agents may be useful signaling mechanisms to issues that need to be considered as we try 5–7 to treat cancer. This contrasts with other death ligands, to manipulate TRAIL signaling to treat cancer. such as TNF or Fas ligand, which activate similar pathways using the same signaling proteins but display unacceptable (J

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jun 1, 2007

References

  • Safety and antitumor activity of recombinant soluble Apo2 ligand
    Ashkenazi
  • Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
    Walczak
  • Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4
    Chuntharapai
  • Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
    Ichikawa
  • Apo2L/TRAIL and its death and decoy receptors
    LeBlanc
  • TRAIL and apoptosis induction by TNF-family death receptors
    Wang
  • Death to the bad guys: targeting cancer via Apo2L/TRAIL
    Bouralexis
  • TRAIL-R as a negative regulator of innate immune cell responses
    Diehl
  • CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
    Janssen
  • T cells require TRAIL for optimal graft-versus-tumor activity
    Schmaltz
  • Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
    Takeda
  • Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer
    Seki
  • Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice
    Cretney
  • Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice
    Yue
  • Cutting edge: TRAIL deficiency accelerates hematological malignancies
    Zerafa
  • DR5 knockout mice are compromised in radiation-induced apoptosis
    Finnberg
  • Extensive regions of the FADD death domain are required for binding to the TRAIL receptor DR5
    Thomas
  • Direct binding of FADD to the TRAIL receptor DR5 is regulated by the death effector domain of FADD
    Thomas
  • The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation
    Thomas
  • A unified model for apical caspase activation
    Boatright
  • FADD self-association is required for stable interaction with an activated death receptor
    Sandu
  • Two CD95 (APO1/Fas) signaling pathways
    Scaffidi
  • Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
    Luo
  • Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand
    Varfolomeev
  • TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB
    Ehrhardt
  • Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects
    Baader
  • Nonapoptotic functions of FADD-binding death receptors and their signaling molecules
    Park
  • Does CD95 have tumor promoting activities?
    Peter
  • TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma
    Trauzold
  • Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation
    Legler
  • Differential regulation of TNF-R1 signaling: lipid raft dependency of p42mapk/erk2 activation, but not NF-kappaB activation
    Doan